Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-O-Methyl-d-glucose is a non-metabolizable glucose analogue, a D-aldohexose derived from D-glucose with a methyl group substitution at position 3. It is not phosphorylated by hexokinase and is primarily utilized as a research tool and marker to assess glucose transport in various cells and organ systems, including studies on blood-brain barrier transport and hexose distribution in the brain. It has also been investigated for its role in diabetes research, particularly in understanding glucose metabolism and insulin response, and has shown an ability to inhibit glucose-induced insulin release. It is not a naturally occurring metabolite.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-O-Methyl-d-glucose.